Last reviewed · How we verify
Etoposide + carboplatin; Etoposide + cisplatin
Etoposide + carboplatin; Etoposide + cisplatin is a Chemotherapy combination (topoisomerase II inhibitor + platinum agent) Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Small cell lung cancer, Ovarian cancer, Testicular cancer.
Etoposide is a topoisomerase II inhibitor that causes DNA damage, combined with platinum agents (carboplatin or cisplatin) that cross-link DNA, working synergistically to kill cancer cells.
Etoposide is a topoisomerase II inhibitor that causes DNA damage, combined with platinum agents (carboplatin or cisplatin) that cross-link DNA, working synergistically to kill cancer cells. Used for Small cell lung cancer, Ovarian cancer, Testicular cancer.
At a glance
| Generic name | Etoposide + carboplatin; Etoposide + cisplatin |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy combination (topoisomerase II inhibitor + platinum agent) |
| Target | Topoisomerase II (etoposide); DNA (carboplatin/cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Etoposide inhibits topoisomerase II, preventing DNA religation and causing double-strand breaks. Carboplatin and cisplatin are platinum-based chemotherapy agents that form covalent DNA adducts, creating inter- and intra-strand cross-links. The combination exploits different mechanisms of DNA damage to enhance cytotoxicity against rapidly dividing cancer cells.
Approved indications
- Small cell lung cancer
- Ovarian cancer
- Testicular cancer
- Lymphomas
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Secondary malignancy
Key clinical trials
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (PHASE3)
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etoposide + carboplatin; Etoposide + cisplatin CI brief — competitive landscape report
- Etoposide + carboplatin; Etoposide + cisplatin updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Etoposide + carboplatin; Etoposide + cisplatin
What is Etoposide + carboplatin; Etoposide + cisplatin?
How does Etoposide + carboplatin; Etoposide + cisplatin work?
What is Etoposide + carboplatin; Etoposide + cisplatin used for?
Who makes Etoposide + carboplatin; Etoposide + cisplatin?
What drug class is Etoposide + carboplatin; Etoposide + cisplatin in?
What development phase is Etoposide + carboplatin; Etoposide + cisplatin in?
What are the side effects of Etoposide + carboplatin; Etoposide + cisplatin?
What does Etoposide + carboplatin; Etoposide + cisplatin target?
Related
- Drug class: All Chemotherapy combination (topoisomerase II inhibitor + platinum agent) drugs
- Target: All drugs targeting Topoisomerase II (etoposide); DNA (carboplatin/cisplatin)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Ovarian cancer
- Indication: Drugs for Testicular cancer
- Compare: Etoposide + carboplatin; Etoposide + cisplatin vs similar drugs
- Pricing: Etoposide + carboplatin; Etoposide + cisplatin cost, discount & access